# US 2008/0305152 A1 · Methods of Inducing Melanogenesis in a Subject

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0305152 A1
- Document ID: US20080305152A1
- Status: Published application
- Kind: A1
- Application number: 11/659,178
- Filed: 2005-02-11
- Published: 2008-12-11
- Earliest claimed: 2004-08-04
- Assignees: Clinuvel Pharmaceuticals Limited
- Inventors: Michael John Kleinig; Thomas R. Tice; Jay K. Staas
- Web page: https://patentgrep.com/patent/US20080305152A1

## CPC

- A61K 38/34: Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
- A61K 8/64: Proteins; Peptides; Derivatives or degradation products thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61Q 19/04: for chemically tanning the skin (topical sun or radiation screening or tanning preparations A61Q17/04)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.

## Claims

### Claim 1

A method for inducing melanogenesis in a human subject comprising administering to the subject an alpha-MSH analogue in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject without inducing homologous desensitization of the melanocortin-1 receptors of the subject.

### Claim 2

A method for inducing melanogenesis in a human subject comprising administering to the subject an effective amount of an alpha-MSH analogue to induce melanogenesis by the melanocytes in epidermal tissue of the subject, wherein the alpha-MSH analogue is administered at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 3

A method for preventing UV radiation-induced skin damage in a human subject comprising administering to the subject an alpha-MSH analogue in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject without inducing homologous desensitization of the melanocortin-1 receptors of the subject.

### Claim 4

A method for preventing UV radiation-induced skin damage in a human subject comprising administering to the subject an alpha-MSH analogue in an effective amount and time, wherein the alpha-MSH analogue is administered at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is administered at a level not exceeding 5 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is administered at a level not exceeding 2 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 7 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is selected from:
(a) compounds of the formula:
Ac-Ser-Tyr-Ser-M-Gln-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2
wherein M is Met, Nle or Lys; and
(b) compounds of the formula:
R1-W-X-Y-Z-R2
wherein
R1 is Ac-Gly-, Ac-Met-Glu, Ac-Nle-Glu-, or Ac-Tyr-Glu-;
W is -His- or -D-His-;
X is -Phe-, -D-Phe-, -Tyr-, -D-Tyr-, or -(pNO2)D-Phe7-;
Y is -Arg- or -D-Arg-;
Z is -Trp- or -D-Trp-; and
R2 is —NH2; -Gly-NH2; or -Gly-Lys-NH2.

### Claim 8 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is a cyclic analogue wherein an intramolecular interaction exists (1) between the amino acid residue at position 4 and an amino acid residue at position 10 or 11, and/or (2) between the amino acid residue at position 5 and the amino acid residue at position 10 or 11.

### Claim 9 (depends on 8)

The method of claim 8, wherein the intramolecular interaction is a disulfide bond or other covalent bond.

### Claim 10 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is selected from the group consisting of:
Ac-Ser-Try-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2
Ac-Ser-Try-Ser-Nle-Asp-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2
Ac-Nle-Glu-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-Gly-Pro-Val-NH2
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH2
Ac-Nle-Glu-His-D-Phe-Arg-Trp-Lys-NH2
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2
Ac-Nle-Glu-His-D-Phe-Arg-Trp-Orn-NH2
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Orn-NH2
Ac-Nle-Glu-His-D-Phe-Arg-Trp-Dab-NH2
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Dab-NH2
Ac-Nle-Glu-His-D-Phe-Arg-Trp-Dpr-NH2
Ac-Nle-Glu-His-Phe-Arg-Trp-Lys-NH2
Ac-Nle-Asp-His-Phe-Arg-Trp-Lys-NH2

### Claim 11 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is selected from the group consisting of:

### Claim 12 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is
[D-Phe7]-alpha-MSH,
[Nle4, D-Phe7]-alpha-MSH,
[D-Ser1, D-Phe7]-alpha-MSH,
[D-Tyr2, D-Phe7]-alpha-MSH,
[D-Ser3, D-Phe7]-alpha-MSH,
[D-Met4, D-Phe7]-alpha-MSH,
[D-Glu5, D-Phe7]-alpha-MSH,
[D-His6, D-Phe7]-alpha-MSH,
[D-Phe7, D-Arg8]-alpha-MSH,
[D-Phe7, D-Trp9]-alpha-MSH,
[D-Phe7, D-Lys11]-alpha-MSH,
[D-Phe-7, D-Pro12]-alpha-MSH,
[D-Phe7, D-Val13]-alpha-MSH,
[D-Ser1, Nle4, D-Phe7]-alpha-MSH,
[D-Tyr2, Nle4, D-Phe7]-alpha-MSH,
[D-Ser3, Nle4, D-Phe7]-alpha-MSH,
[Nle4, D-Glu5, D-Phe7]-alpha-MSH,
[Nle4, D-His6, D-Phe7]-alpha-MSH,
[Nle4, D-Phe7, D-Arg8]-alpha-MSH,
[Nle4, D-Phe7, D-Trp9]-alpha-MSH,
[Nle4, D-Phe7, D-Lys11]-alpha-MSH,
[Nle4, D-Phe7, D-Pro12]-alpha-MSH,
[Nle4, D-Phe7, D-Val13]-alpha-MSH,
[Nle4, D-Phe7]-alpha-MSH4-10,
[Nle4, D-Phe7]-alpha-MSH4-11,
[D-Phe7]-alpha-MSH5-11,
[Nle4, D-Tyr7]-alpha-MSH4-11,
[(pNO2)D-Phe7]-alpha-MSH4-11,
[Tyr4, D-Phe7]-alpha-MSH4-10,
[Tyr4, D-Phe7]-alpha-MSH4-11,
[Nle4]-alpha-MSH4-11,
[Nle4, (pNO2)D-Phe7]-alpha-MSH4-11,
[Nle4, D-His6]-alpha-MSH4-11,
[Nle4, D-His6, D-Phe7]-alpha-MSH4-11,
[Nle4, D-Arg8]-alpha-MSH4-11,
[Nle4, D-Trp9]-alpha-MSH4-11,
[Nle4, D-Phe7, D-Trp9]alpha-MSH4-11,
[Nle4, D-Phe7]-alpha-MSH4-9, or
[Nle4, D-Phe7, D-Trp9]-alpha-MSH4-9.

### Claim 13 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is
[Nle4, D-Phe7]-alpha-MSH4-10,
[Nle4, D-Phe7]-alpha-MSH4-11,
[Nle4, D-Phe7, D-Trp9]-alpha-MSH4-11, or
[Nle4, D-Phe7]-alpha-MSH4-9.

### Claim 14 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is [Nle4, D-Phe7]-alpha-MSH.

### Claim 15 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is administered orally or parenterally.

### Claim 16 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is administered intravenously, intramuscularly, subcutaneously, intraperitoneally, intradermally, ocularly, rectally, vaginally, transdermally, topically, buccally, sublingually, mucosally, or by inhalation.

### Claim 17 (depends on 1)

The method as claimed in claim 1, wherein the alpha-MSH analogue is administered in a delivery system.

### Claim 18 (depends on 17)

The method of claim 17, wherein the delivery system comprises a fiber, a microparticle, a microsphere, a microcapsule, a nanosphere, a nanocapsule, a porous silicone nanoparticle, an in situ gelling formulation, an in situ bolus forming composition, a tablet, a buccal patch, a film, tablets, an osmotic driven formulation, a capsule, a liquid filled capsule, a liposome, a hydrogel formulation, an emulsion, a microemulsion, or a suspension.

### Claim 19 (depends on 17)

The method of claim 17, wherein the delivery system comprises a rod or implant comprising a polymer.

### Claim 20 (depends on 17)

The method of claim 17, wherein the delivery system further comprises a pharmaceutically-acceptable component encapsulated in the delivery system.

### Claim 21 (depends on 20)

The method of claim 20, wherein the pharmaceutically-acceptable component comprises a fatty acid, a sugar, a salt, a water-soluble polymer, a protein, polysaccharide, a carboxmethyl cellulose, a surfactant, a plasticizer, a high- or low-molecular-weight porosigen, or a hydrophobic low-molecular-weight compound.

### Claim 22 (depends on 19)

The method of claim 19, wherein the polymer comprises a silicone, a poly(diene), a poly(alkene), a poly(acrylic), a poly(methacrylic), poly(vinyl ether), a poly(vinyl alcohol), a poly(vinyl ketone), a poly(vinyl halide), a poly(vinyl nitrile), a poly(vinyl ester), a poly(vinyl pyridine), poly(5-methyl-2-vinyl pyridine), a poly(styrene), a poly(carbonate), a poly(ester), a poly(orthoester), a poly(esteramide), a poly(anhydride), a poly(urethane), a poly(amide), a cellulose ether, a cellulose ester, a poly(saccharide), a protein, gelatin, starch, a gum, or a resin.

### Claim 23 (depends on 19)

The method of claim 19, wherein the polymer comprises a biodegradable polymer, a non-biodegradable polymer, or a combination thereof.

### Claim 24 (depends on 23)

The method of claim 23, wherein the non-biodegradable polymer comprises a polyacrylate, a polymer of an ethylene-vinyl acetate, an acyl substituted cellulose acetate, a non-degradable polyurethane, a polystyrene, polyvinyl chloride, polyvinyl fluoride, poly(vinyl imidazole), a chlorosulphonate polyolefin, polyethylene oxide, a blend thereof, or copolymer thereof.

### Claim 25 (depends on 23)

The method of claim 23, wherein the biodegradable polymer comprises a poly(caprolactone), a poly(orthoester), a poly(phosphazene), a poly(hydroxybutyrate) or a copolymer containing poly(hydroxybutarate), a poly(lactide-co-caprolactone), a polycarbonate, a polyesteramide, a polyanhydride, a poly(dioxanone), a poly(alkylene alkylate), a copolymer of polyethylene glycol and polyorthoester, a biodegradable polyurethane, a poly(amino acid), a polyetherester, a polyacetal, a polycyanoacrylate, poly(oxyethylene)/poly(oxypropylene) copolymer, a blend thereof, or a copolymer thereof.

### Claim 26 (depends on 23)

The method of claim 23, wherein the biodegradable polymer comprises a poly(lactide), a poly(glycolide), a poly(lactide-co-glycolide), a poly(lactic acid), a poly(glycolic acid), a poly(lactic acid-co-glycolic acid), or a mixture thereof.

### Claim 27 (depends on 26)

The method of claim 26, wherein the biodegradable polymer is blocked.

### Claim 28 (depends on 26)

The method of claim 26, wherein the biodegradable polymer is unblocked.

### Claim 29 (depends on 26)

The method of claim 26, wherein the biodegradable polymer comprises a polymer formed from components comprising 40 to 100 mole % lactide and from 0 to 60 mole % glycolide.

### Claim 30 (depends on 26)

The method of claim 26, wherein the biodegradable polymer comprises 85:15 poly(lactide-co-glycolide).

### Claim 31 (depends on 26)

The method of claim 26, wherein the biodegradable polymer comprises 75:25 poly(lactide-co-glycolide).

### Claim 32 (depends on 26)

The method of claim 26, wherein the biodegradable polymer comprises poly(lactide).

### Claim 33 (depends on 26)

The method of claim 26, wherein the biodegradable polymer has an intrinsic viscosity of from 0.15 to 1.5 dL/g as measured in chloroform at a concentration of 0.5 g/dL at 30° C.

### Claim 34 (depends on 26)

The method of claim 26, wherein the biodegradable polymer has an intrinsic viscosity of from 0.25 to 1.5 dL/g as measured in chloroform at a concentration of 0.5 g/dL at 30° C.

### Claim 35 (depends on 17)

The method of claim 17, wherein the amount of alpha-MSH analogue in the delivery system is up to 50% by weight.

### Claim 36 (depends on 17)

The method of claim 17, wherein the amount of alpha-MSH analogue in the delivery system is from 5 to 60% by weight.

### Claim 37 (depends on 17)

The method of claim 17, wherein the delivery system comprises an implant or rod, wherein the alpha-MSH analogue is [Nle4, D-Phe7]-alpha-MSH in an amount of from 15% to 45% by weight of the implant or rod, and wherein the rod or implant comprises poly(lactide) or poly(lactide-co-glycolide).

### Claim 38 (depends on 37)

The method of claim 37, wherein when the implant or rod comprises poly(lactide-co-glycolide), the poly(lactide-co-glycolide) comprises 85:15 poly(lactide-co-glycolide).

### Claim 39 (depends on 17)

The method as claimed in claim 17, wherein the delivery system is administered subcutaneously to the subject.

### Claim 40 (depends on 17)

The method as claimed in claim 17, wherein the delivery system releases the alpha-MSH analogue for a period of at least 2 days.

### Claim 41 (depends on 17)

The method as claimed in claim 17, wherein the delivery system releases the alpha-MSH analogue for a period of at least 10 days.

### Claim 42 (depends on 17)

The method as claimed in claim 17, wherein the delivery system releases the alpha-MSH analogue in the subject for at least 20 days.

### Claim 43 (depends on 17)

The method as claimed in claim 17, wherein the delivery system releases the alpha-MSH analogue in the subject for at least 30 days.

### Claim 44 (depends on 1)

The method as claimed in claim 1 wherein the alpha-MSH analogue is administered in a transdermal formulation.

### Claim 45 (depends on 44)

The method of claim 44, wherein the amount of alpha-MSH analogue in the formulation is 0.001 to 10% by weight.

### Claim 46 (depends on 44)

The method of claim 44, wherein the amount of alpha-MSH analogue in the formulation is 0.05 to 5% by weight.

### Claim 47

(canceled)

### Claim 48

(canceled)

### Claim 49

(canceled)

### Claim 50

(canceled)

### Claim 51

A composition for inducing melanogenesis in a human subject, wherein the composition administers an alpha-MSH analogue to the subject in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject without inducing homologous desensitization of the melanocortin-1 receptors of the subject.

### Claim 52

A composition for inducing melanogenesis in a human subject, wherein the composition administers an alpha-MSH analogue to the subject at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 53

A composition for preventing UV radiation-induced skin damage in a human subject, wherein the composition administers an alpha-MSH analogue to the subject in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of the subject without inducing homologous desensitization of the melanocortin-1 receptors of the subject.

### Claim 54

A composition for preventing UV radiation-induced skin damage in a human subject, wherein the composition administers an alpha-MSH analogue to the subject at a level not exceeding 10 ng/ml in the plasma of the subject for a period of at least 24 hours.

### Claim 55 (depends on 51)

A composition as claimed in claim 51, comprising said alpha-MSH analogue together with one or more pharmaceutically acceptable carriers and/or diluents.

### Claim 56 (depends on 55)

A composition as claimed in claim 55, which comprises a delivery system.

### Claim 57 (depends on 56)

A composition as claimed in claim 56, wherein the delivery system comprises a rod or implant comprising a polymer.

### Claim 58 (depends on 57)

A composition as claimed in claim 57, wherein the polymer comprises a biodegradable polymer, a non-biodegradable polymer, or a combination thereof.

### Claim 59 (depends on 57)

A composition as claimed in claim 57, wherein the delivery system comprises an implant or rod, where the alpha-MSH analogue is [Nle4, D-Phe7]-alpha-MSH in an amount of from 15% to 45% by weight of the implant or rod, and wherein the rod or implant comprises poly(lactide) or poly(lactide-co-glycolide).

### Claim 60 (depends on 55)

A composition as claimed in claim 55, wherein the composition is a transdermal formulation.
